AAPL 154.88 +1.84 (+1.20%)MSFT 105.38 +0.38 (+0.36%)FB 130.65 -2.52 (-1.89%)ZNGA 3.95 +0.07 (+1.68%)NVDA 133.37 -0.29 (-0.22%)WBA 68.22 +0.16 (+0.24%)GOOG 1029.8 -7.78 (-0.75%)PIH 4.14 +0.25 (+6.43%)
AAPL 154.88 +1.84 (+1.20%)MSFT 105.38 +0.38 (+0.36%)FB 130.65 -2.52 (-1.89%)ZNGA 3.95 +0.07 (+1.68%)NVDA 133.37 -0.29 (-0.22%)WBA 68.22 +0.16 (+0.24%)GOOG 1029.8 -7.78 (-0.75%)PIH 4.14 +0.25 (+6.43%)

Balance Sheet ACHN Quote Achillion P

All | Income Statement | Balance Sheet | Cash Flow | Retained Earnings | PPE Schedule | Intangible and Goodwill Schedule
Year 201420152016
CashAndCashEqui 82 77 43
ShortTermInvest 378 287 257
Cash 459 364 300
AccountReceivab 2 15 2
Inventories 0 0 0
DeferredIncomeT 0 0 0
OtherCurrentAss 0 2 0
TotalCurrentAss 463 383 304
PPE 8 11 11
AccumulatedDepr -6 -7 -8
NetPPE 2 3 3
EquityAndOtherI 0 28 31
Goodwill 0 0 0
IntangibleAsset 0 0 0
OtherLTAssets 0 0 0
TotalNonCurrent 2 31 34
TotalAssets 465 414 338
ShortTermDebt 0 0 0
AccountsPayable 4 7 5
TaxesPayable 0 0 0
AccruedLiabilit 10 7 7
DeferredRevenue 0 0 0
OtherCurrentLia 0 0 0
TotalCurrentLia 15 14 13
Debt 0 0 0
DeferredTaxesLi 0 0 0
DeferredRevenue 0 0 0
OtherLTLiabilit 0 0 0
TotalNonCurrent 0 0 0
TotalLiabilitie 15 14 13
CommonStock 0 0 0
AdditionalPaidI 905 917 927
RetainedEarning -456 -517 -603
AccumulatedOthe 0 0 0
TotalStockholde 450 399 325
TotalLiabilitie 465 414 338
Achillion Pharmaceuticals Inc. income statement is the only one that provides an overview of company sales and net income
The reasoning behind the adjustment, however, is that free cash flow is meant to measure money being spent right now, not transactions that happened in the past. This makes Achillion Pharmaceuticals Inc. FCF a useful instrument for identifying growing companies with high up-front costs, which may eat into earnings now but have the potential to pay off later.